Navigation Links
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2009

ially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achie
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
2. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
5. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
6. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
7. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
...  Cenestra Health announces that the U.S. Patent and Trademark ... No. 8,071,646 (the ",646 patent"), that protects and provides ... acid (EPA) and docosahexaenoic acid (DHA) in ratios ranging ... provides exclusivity for these EPA:DHA ratios in compositions with ...
... of up to 25 percent in two barely separated ... Designers of next-generation devices using nanowires to deliver electric ... solar arrays may need to make allowances for ... for 20 years," says Sandia lead researcher Mike Lilly. ...
... RATON, Fla., Dec. 7, 2011 /PRNewswire-iReach/ -- ... Herb Pharma, Switzerland: the best and most powerful weapons ... Although aging is a natural process, no-one ... neck and decolletage, which are on display most of ...
Cached Biology Technology:Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 2Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations 3Voltage increases up to 25 percent observed in closely packed nanowires at Sandia Labs 2Voltage increases up to 25 percent observed in closely packed nanowires at Sandia Labs 3Fytofontana Cosmeceuticals: The Swiss Secret For Incredibly Young And Beautiful Skin 2
(Date:4/17/2014)... Sodium channels are implicated in many serious conditions such ... important potential target for drug therapies. Unfortunately, there is ... New Cambridge research provides fresh and unexpected insight into ... its components - β-subunit molecules - which are responsible ... is published in the most recent edition of the ...
(Date:4/17/2014)... genetic information of DNA is used to manufacture ... different functions in living organisms. Messenger RNA (mRNA) ... by relating the genetic information of DNA to ... , By examining the different types and amounts ... a given time, researchers can determine which specific ...
(Date:4/17/2014)... International researchers, led by the Australian National University ... sea-level changes and deep-sea temperature variability over the ... scientists better understand the climate surrounding ice ages ... help determine the relationship between carbon dioxide levels, ... ANU, the University of Southampton (UoS) and the ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2
... has long been used topically in many skin creams ... for the skin. Now, new research just published in ... consuming flavanol-rich cocoa and how it might actually benefit ... certain components in cocoa may actually help improve the ...
... vaccines may increase elderly patients' immune response without ... protection against the flu, according to an article ... Internal Medicine, one of the JAMA/Archives journals. , ... for 50 years to prevent flu and its ...
... the Stanford University School of Medicine have taken a ... that could eventually be transplanted into living organisms. , ... resident Oscar Abilez, MD, and colleagues have successfully differentiated ... blocks of blood vessels, after placing them in a ...
Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2High-dose flu vaccines appear to safely boost immunity in elderly 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3
... for Membrane Proteins ,Contains sufficient components ... for 2-D gel analysis , ,Includes:, ... , (contains sufficient reagents for ... cell weight of 10 mg each) Kit ...
... The Amplifluor UniPrimer-fluorescein is a hairpin ... transfer pair (fluorescein and non-fluorescent quencher) ... The UniPrimer is identical to ... Universal Detection System (S7901) and is ...
...
Mouse monoclonal antibody raised against a partial recombinant EBI3. NCBI Entrez Gene ID = EBI3...
Biology Products: